Business Wire

2023 NAB Show®: Kalray Unveils ngenea®2, A Major Evolution of Its Open Data Management Platform, and Demonstrates It With AWS and Seagate

13.4.2023 20:35:00 EEST | Business Wire | Press release

Share

Kalray (Euronext Growth Paris : ALKAL), today announced the release of ngenea®2, the new version of its open data management and orchestration platform for data-centric applications. Leveraging Kalray’s Data Processor Unit (DPU) acceleration cards and Kalray’s pixstor™ software-defined storage solution, ngenea®2 addresses the challenges faced by a growing number of companies across all industries to be able to process, store, and manage their data faster, more efficiently, and more securely, wherever the data is located and whatever application they use.

ngenea®2 will be demonstrated at NAB 2023 by pixitmedia, Kalray’s subsidiary specialized in storage and data management solutions for the Media & Entertainment industry, in the Amazon (AWS) Innovation Zone and in the booth of its technology partner Seagate.

NEW ADVANCED FEATURES BOOSTED BY KALRAY DPU TECHNOLOGY

An increasing number of companies face challenges in their abilities to store, access, process, and control their data easily and efficiently when working within domains such as HPC, life science, media, finance, and manufacturing, to name a few. ngenea® offers a unique solution to address these challenges. It automates data management to ensure simple and efficient access to data wherever it is needed, on premises or in the cloud, and allows developers and data analysts to run complex data-intensive workflows in an easy and cost-efficient way.

ngenea®2 introduces advanced features to further address these needs. ngenea®2 consolidates data and infrastructure management into a single point of orchestrated control, enabling developers and data scientists to launch new, globally accessible data-centric workflows in seconds, across multiple on-premises, public and private cloud endpoints simultaneously and securely through each phase of their development. ngenea®2 exposes easy-to-use interfaces (“APIs”) to allow integration of third-party storage and application solutions into the ngenea namespace, providing a unified view of and instant global access to real-time data for developers. Moreover, one major evolution of ngenea®2 is its ability to leverage Kalray’s DPUs. With Kalray’s DPUs, ngenea®2 has been designed to give developers the best performance through in-storage NVMe processing and to offer AI-assisted unprecedented levels of insight into unstructured content assets to facilitate data-centric workflows.

DISPLAYING THE LATEST TECHNOLOGIES AT THE MECCA OF BROADCASTING

NAB, held from April 15-19, 2023 in Las Vegas, is one of the largest gatherings of Media & Entertainment (M&E) professionals in the world, featuring the latest technologies, services, and products in the areas of broadcasting, streaming, production, post-production, content creation, and distribution.

At the show, Kalray, through its subsidiary pixitmedia, will demonstrate multiple use cases to highlight how ngenea®2 manages and orchestrates global M&E workflows in diverse environments that include products and services from various technology partners, including AWS and Seagate, but also Adobe, Autodesk, Avid, Blackmagic, and Projective.

DEMONSTRATING AN END-TO-END CLOUD WORKFLOW AT AWS INNOVATION ZONE

At its kiosk in the Amazon Web Services (AWS) Create Innovation Zone (North Hall N2562H), pixitmedia will display a mixed editorial environment in AWS, mirroring a solution that it has in production with a Media & Entertainment Distribution arm of a major motion picture studio.

The demonstration will showcase how Kalray’s pixstor™ and ngenea®2 bring new levels of coherence and efficiency to media production, while improving security, controlling costs, and boosting collaboration. This solution includes an Amazon Elastic Compute Cloud (EC2) workstation in a pixstor™ cloud, with Projective’s Strawberry providing project containerization of a shared storage environment, enabling Adobe, Avid, and Blackmagic DaVinci Resolve participation in the workflow – all using the same core assets.

DEMONSTRATING AUTOMATED MOVEMENT OF MEDIA WITH SEAGATE AND AUTODESK

Also, technology partner Seagate is hosting pixitmedia to display a joint hyperconverged solution with three high-end workstations running Autodesk Flame, Flame Assist, and Blackmagic DaVinci Resolve. The demonstrated solution provides high-performance finishing suites, leveraging high-speed, native access to media data on pixstor™, boosted by Kalray hardware DPU accelerator cards and with ngenea®2 automating the movement of media between a customer NAS, Avid NEXIS, and Tier0 storage.

ABOUT KALRAY

Kalray is a leading provider of hardware and software technologies and solutions for high-performance, data centric markets, from edge to cloud.

Kalray provides a full range of products to enable smarter, more efficient, and energy-wise data-intensive applications and infrastructures. Its offers include its unique patented DPU (Data Processing Unit) processors and acceleration cards as well as its leading-edge software-defined storage and data management offers. Separated or in combination, Kalray’s high-performance solutions allow its customers to improve the efficiency of data centers or design the best solutions in fast-growing sectors such as AI, Media & Entertainment, Life Science, Scientific Research, Edge Computing, Automotive and others.

Founded in 2008 as a spin-off of the well-known French CEA research lab, with corporate and financial investors such as Alliance Venture (Renault-Nissan-Mitsubishi), NXP Semiconductors or Bpifrance, Kalray is dedicated through technology, expertise, and passion to offer more: more for a smart world, more for the planet, more for customers and developers. www.kalrayinc.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

INVESTOR CONTACTS

E ric BAISSUS
contactinvestisseurs@kalrayinc.com
Phone: + 33 4 76 18 90 71

ACTUS Finance & Communication
Anne-Pauline PETUREAUX
kalray@actus.fr
Phone: + 33 1 53 67 36 72

PRESS CONTACTS

S ylvie DAM
communication@kalrayinc.com
Phone: +33 4 76 18 90 71

ACTUS Finance & Communication
Serena BONI
sboni@actus.fr
Phone: +33 4 72 18 04 92

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye